SOM Biotech closed €2M funding round on January 2017 where 18 international investors from 10 different countries participated such as Monaco, Poland, UK, USA, India and South Korea among others. Most of the super-business angels involved include former pharmaceutical executives, which shows trust in SOM’s business model and its future vision. Additionally, SOM Biotech opened…
SOM Biotech closed €2M funding round and opens €10M Series A
posted on June 27, 2017
SOM Biotech at World Orphan Drug Congress USA 2017
posted on June 27, 2017
SOM Biotech attended the World Orphan Drug Congress USA 2017 (WODC) hold in Washington, USA on April 19th-21st. More than 1,000 global attendees did not want to miss the opportunity to discuss the latest trends on Orphan Drugs, a $140Billion dollar market. Topics like pricing, reimbursement, M&A, commercialization, FDA’s considerations, scientific innovation, regional market analysis…
SOM Biotech at BIO Convention 2017
posted on June 13, 2017
SOM Biotech attended last BIO Convention on June 19th-22nd 2017 in San Diego, CA. Michael Greenberg, VP of Business Development, was in attendance. He had the opportunity to discuss potential partnerships on CNS or Orphan Drugs space with several biotech/pharma companies. If you are interested in hearing about SOM’s latest developments, please contact our Business…
SOM Biotech stands for Responsible Innovation
posted on June 7, 2017
SOM Biotech is one of the European companies participating in the EU Compass program, Biomedicine field. COMPASS is an EU-funded project that supports Small and Medium-sized Enterprises (SMEs) in three emerging technology industries in order to manage their research, development and innovation activities in a responsible and inclusive manner. Dr. Esteva, SOM’s Operations Manager, takes part…
SOM Biotech announces a worldwide license with Corino Therapeutics, Inc. for SOM0226, a drug for the treatment of TTR Amyloidosis.
posted on May 23, 2017
SOM Biotech Ltd (SOM) a leading clinical-stage biopharmaceutical company specialized in drug repurposing to treat rare diseases with a focus on CNS diseases, today announces an exclusive worldwide license agreement with U.S. based Corino Therapeutics, Inc. (Corino), for the clinical development and commercialization of SOM0226 (CRX-1008), a drug for the treatment of Transthyretin Amyloidosis (ATTR).…
SOM Biotech SL Announces New Logo and Website Launch
posted on April 19, 2017
The new and completely redesigned website offers quick and easy access to essential and relevant information on SOM Biotech. This renewed design is aligned with the ambitious stage SOM Biotech is currently entering. After closing a successful €2M round and with its first large program out licensed (SOM0226 for TTR Amyloidosis), SOM Biotech is going…